AbbVie’s Rinvoq (upadacitinib) has been granted marketing authorisation by the European Commission (EC) to treat giant cell ...

In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Buy rating on AbbVie (ABBV – Research Report), with a price target ...

Investing isn’t easy, and given the current market volatility, retail investors are on edge, worrying about their portfolios.

Ironwood Pharmaceuticals (IRWD) is undergoing a challenging transition with LINZESS but has promising growth potential with ...

Fremanezumab is a calcitonin-gene related peptide (CGRP) pathway monoclonal antibody that is FDA approved for adults with both episodic and chronic migraine.

A wild ride in an escalating trade war has torn at Big Pharma’s shares while global markets flag in the back-and-forth winds.

With US tariffs on almost every country now in effect, Americans are lamenting pending prices hikes for Champagne, Parmesan ...

During the 1960s, Abbott entered the Japanese market through a joint venture with Dainippon Pharmaceutical Co., Ltd ... The creation of AbbVie In 2011, Abbott announced it was to separate into ...

The drug-funding agency estimated that 1200 patients would benefit this year, rising to more than 5000 annually after 2030.

Gilead, which is searching for ways to maintain market share following competition from AbbVie and Merck & Co, added that the European Commission had extended the use of its established ...

Learn more about whether Alvotech or Halozyme Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Endlyz is supported by leading investors, including SV Health Investors’ Dementia Discovery Fund, Oxford Science Enterprises, ...